NECTAR Everolimus plus Cisplatin in Triple (-) Breast Cancer

Investigator: Jenny Chang, MD

Study Coordinator: Toniva Boone

Status: Enrolling Number: NCT01931163

Phone: 713.441.0686

IRB Number: Pro00008952


PURPOSE: The purpose of this study is to test how effective combing a Cisplatin chemotherapy with Everolimus is in treating subjects with residual triple negative breast cancer, who have already received chemotherapy prior to surgery.
More to Explore